In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. This agent is actually approved for use in […]

FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer